• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球水痘疫苗效力:荟萃分析。

Global Varicella Vaccine Effectiveness: A Meta-analysis.

机构信息

National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia; and

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

出版信息

Pediatrics. 2016 Mar;137(3):e20153741. doi: 10.1542/peds.2015-3741. Epub 2016 Feb 16.

DOI:10.1542/peds.2015-3741
PMID:26908671
Abstract

CONTEXT

Several varicella vaccines are available worldwide. Countries with a varicella vaccination program use 1- or 2-dose schedules.

OBJECTIVE

We examined postlicensure estimates of varicella vaccine effectiveness (VE) among healthy children.

DATA SOURCES

Systematic review and descriptive and meta-analysis of Medline, Embase, Cochrane libraries, and CINAHL databases for reports published during 1995-2014.

STUDY SELECTION

Publications that reported original data on dose-specific varicella VE among immunocompetent children.

DATA EXTRACTION

We used random effects meta-analysis models to obtain pooled one dose VE estimates by disease severity (all varicella and moderate/severe varicella). Within each severity category, we assessed pooled VE by vaccine and by study design. We used descriptive statistics to summarize 1-dose VE against severe disease. For 2-dose VE, we calculated pooled estimates against all varicella and by study design.

RESULTS

The pooled 1-dose VE was 81% (95% confidence interval [CI]: 78%-84%) against all varicella and 98% (95% CI: 97%-99%) against moderate/severe varicella with no significant association between VE and vaccine type or study design (P > .1). For 1 dose, median VE for prevention of severe disease was 100% (mean = 99.4%). The pooled 2-dose VE against all varicella was 92% (95% CI: 88%-95%), with similar estimates by study design.

LIMITATIONS

VE was assessed primarily during outbreak investigations and using clinically diagnosed varicella.

CONCLUSIONS

One dose of varicella vaccine was moderately effective in preventing all varicella and highly effective in preventing moderate/severe varicella, with no differences by vaccine. The second dose adds improved protection against all varicella.

摘要

背景

全球有多种水痘疫苗可供使用。实施水痘疫苗接种计划的国家采用 1 剂或 2 剂方案。

目的

我们研究了上市后水痘疫苗效力(VE)在健康儿童中的估计值。

数据来源

对 1995 年至 2014 年期间发表的 Medline、Embase、Cochrane 图书馆和 CINAHL 数据库中的系统评价和描述性及荟萃分析进行了系统性评价。

研究选择

报告了免疫功能正常儿童中剂量特异性水痘 VE 的原始数据的出版物。

数据提取

我们使用随机效应荟萃分析模型,根据疾病严重程度(所有水痘和中度/重度水痘)获得了单剂量 VE 的汇总估计值。在每个严重程度类别中,我们评估了疫苗和研究设计对汇总 VE 的影响。我们使用描述性统计数据总结了针对严重疾病的 1 剂 VE。对于 2 剂 VE,我们计算了针对所有水痘和研究设计的汇总估计值。

结果

1 剂 VE 对所有水痘的汇总估计值为 81%(95%置信区间[CI]:78%-84%),对中度/重度水痘的汇总估计值为 98%(95%CI:97%-99%),与疫苗类型或研究设计之间无显著关联(P>.1)。对于 1 剂,预防严重疾病的 VE 中位数为 100%(均值=99.4%)。2 剂 VE 对所有水痘的汇总估计值为 92%(95%CI:88%-95%),不同研究设计的估计值相似。

局限性

VE 主要在暴发调查期间并使用临床诊断的水痘进行评估。

结论

1 剂水痘疫苗对预防所有水痘具有中等效力,对预防中度/重度水痘具有高度效力,且疫苗之间无差异。第二剂可提高对所有水痘的保护效果。

相似文献

1
Global Varicella Vaccine Effectiveness: A Meta-analysis.全球水痘疫苗效力:荟萃分析。
Pediatrics. 2016 Mar;137(3):e20153741. doi: 10.1542/peds.2015-3741. Epub 2016 Feb 16.
2
Vaccines for measles, mumps, rubella, and varicella in children.儿童麻疹、腮腺炎、风疹和水痘疫苗。
Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD004407. doi: 10.1002/14651858.CD004407.pub5.
3
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
4
Vaccines for preventing herpes zoster in older adults.用于预防老年人带状疱疹的疫苗。
Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5.
5
Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis.肺炎球菌结合疫苗的免疫原性和血清效力:系统评价和网络荟萃分析。
Health Technol Assess. 2024 Jul;28(34):1-109. doi: 10.3310/YWHA3079.
6
Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.用于儿童和成人水痘(带状疱疹)暴露后预防的疫苗。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001833. doi: 10.1002/14651858.CD001833.pub2.
7
Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.打破循环:针对水痘-带状疱疹病毒的终生疫苗接种策略考量
Expert Rev Vaccines. 2025 Dec;24(1):556-569. doi: 10.1080/14760584.2025.2514527. Epub 2025 Jun 19.
8
Efficacy and safety of COVID-19 vaccines.新型冠状病毒疫苗的有效性和安全性。
Cochrane Database Syst Rev. 2022 Dec 7;12(12):CD015477. doi: 10.1002/14651858.CD015477.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.

引用本文的文献

1
Epidemiological characteristics of breakthrough varicella cases among students in Jiulongpo District, Chongqing: implications for vaccination strategies.重庆市九龙坡区学生突破性水痘病例的流行病学特征:对疫苗接种策略的启示
Front Immunol. 2025 Jun 18;16:1594598. doi: 10.3389/fimmu.2025.1594598. eCollection 2025.
2
Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: a systematic review and meta-analysis.国产和进口减毒活水痘疫苗在中国健康人群中的免疫原性和安全性:一项系统评价和荟萃分析
BMC Infect Dis. 2025 Jul 5;25(1):897. doi: 10.1186/s12879-025-11275-w.
3
Investigation and analysis of influencing factors on the economic burden of varicella disease in Qingyang, China, 2024.
2024年中国庆阳水痘疾病经济负担影响因素的调查与分析
Hum Vaccin Immunother. 2025 Dec;21(1):2521188. doi: 10.1080/21645515.2025.2521188. Epub 2025 Jul 1.
4
Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy.水痘疫苗两剂免疫策略实施10年后的人群血清流行病学调查。
Hum Vaccin Immunother. 2025 Dec;21(1):2512642. doi: 10.1080/21645515.2025.2512642. Epub 2025 Jun 4.
5
Seroprevalence of Varicella-Zoster Virus and the Need for Herpes Zoster Vaccination Among Adults in Saudi Arabia.沙特阿拉伯成年人中水痘-带状疱疹病毒血清阳性率及带状疱疹疫苗接种需求
Cureus. 2025 Mar 21;17(3):e80949. doi: 10.7759/cureus.80949. eCollection 2025 Mar.
6
A fresh look at varicella vaccination.对水痘疫苗接种的新审视。
Hum Vaccin Immunother. 2025 Dec;21(1):2488099. doi: 10.1080/21645515.2025.2488099. Epub 2025 Apr 15.
7
Surveillance of Adverse Events Following Varicella Vaccine Immunization in Zhejiang Province, China, from 2020 to 2022.2020年至2022年中国浙江省水痘疫苗免疫接种后不良事件监测
Vaccines (Basel). 2025 Jan 10;13(1):57. doi: 10.3390/vaccines13010057.
8
Optimizing Varicella Vaccination Strategy: A Study on Age and Dose Impacts on Antibody Levels.优化水痘疫苗接种策略:年龄和剂量对抗体水平影响的研究
Vaccines (Basel). 2024 Dec 30;13(1):23. doi: 10.3390/vaccines13010023.
9
Disseminated vaccine-strain varicella-zoster virus reactivation in an adolescent with secondary immunodeficiency: a case report and literature review.散发型疫苗株水痘-带状疱疹病毒激活在继发免疫缺陷的青少年中的发病:病例报告及文献复习。
BMC Infect Dis. 2024 Nov 14;24(1):1296. doi: 10.1186/s12879-024-09776-1.
10
Analysis of antibody dynamics in Chinese children aged 1-3 years after single-dose varicella vaccination: A 42 months prospective study.1-3 岁儿童单剂水痘疫苗接种后抗体动态分析:42 个月前瞻性研究。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2410065. doi: 10.1080/21645515.2024.2410065. Epub 2024 Oct 16.